首页> 中国专利> 阻断肿瘤源性ILT4在过继性T细胞治疗中的应用

阻断肿瘤源性ILT4在过继性T细胞治疗中的应用

页面导航

摘要
著录项
相似文献

摘要

本发明提供阻断肿瘤源性ILT4在过继性T细胞治疗中的应用。本发明通过研究发现，肿瘤源性ILT4对微环境T细胞老化具诱导作用，并详细探究了其分子及代谢机制，从临床前模型证实了靶向ILT4可以逆转肿瘤的免疫抑制性微环境，参与恶性肿瘤的靶向治疗，并进一步构建B6小鼠恶性黑色素瘤过继性T细胞免疫治疗模型，研究ILT4阻断联合ACT治疗的可行性，为克服ACT治疗耐药提供有效手段。

著录项

公开/公告号CN110917356B

专利类型发明专利
公开/公告日2020-10-27

原文格式PDF
申请/专利权人济南市中心医院;
展开▼

申请/专利号CN201911168509.6
发明设计人高爱琴;孙玉萍;李娟;王淑云;林文俐;王婧男;张方;
展开▼

申请日2019-11-25
分类号A61K45/00(20060101);A61P35/00(20060101);A61P37/04(20060101);
代理机构37221 济南圣达知识产权代理有限公司;
代理人郑平
地址 250013 山东省济南市历下区解放路105号
入库时间 2022-08-23 11:19:00

相似文献

专利
中文文献
外文文献

1. 阻断肿瘤源性ILT4在过继性T细胞治疗中的应用 [P] . 中国专利： CN110917356B . 2020.10.27
2. 阻断肿瘤源性ILT4在过继性T细胞治疗中的应用 [P] . 中国专利： CN110917356A . 2020-03-27
3. compound or a pharmaceutically acceptable salt, solvate or hydrate thereof, pharmaceutical composition, and, methods to inhibit angiogenesis, to inhibit or reduce the polymerization of tubulin or the stability of tubulin in a cell, to inhibit pde4 activity in a cell , to inhibit tumor necrosis factor-alpha (tnf-alpha) activity in a cell, to treat or ameliorate an inflammatory disorder, to treat or ameliorate cancer, to inhibit cancer cell proliferation, to mark, block or destroy tumor vasculature function, to mark, block or destroy tumor vessel endothelium, to mark, block or destroy tumor vasculature function and inhibit angiogenesis in a tumor and to treat or ameliorate a central nervous system disorder [P] . BRPI0514857A . 2008-05-06

机译：化合物或其药学上可接受的盐，溶剂化物或水合物，药物组合物以及抑制血管生成，抑制或降低微管蛋白聚合或微管蛋白稳定性的方法，抑制细胞中pde4活性，抑制肿瘤的方法细胞中的坏死因子-α（tnf-alpha）活性，用于治疗或改善炎症性疾病，治疗或改善癌症，抑制癌细胞增殖，标记，阻断或破坏肿瘤血管功能，标记，阻断或破坏肿瘤血管内皮，标记，阻断或破坏肿瘤的脉管系统功能并抑制肿瘤中的血管生成，并治疗或改善中枢神经系统疾病
4. compound or a pharmaceutically acceptable salt, solvate or hydrate thereof, pharmaceutical composition, and methods for inhibiting angiogenesis, for inhibiting or reducing tubulin polymerization or tubulin stability in a cell, for inhibiting pde4 activity in a cell , to inhibit tumor necrosis factor-alpha (tnf-alpha) activity in a cell, to treat or ameliorate an inflammatory disorder, to treat or ameliorate cancer, to inhibit cancer cell proliferation, to mark, block or destroy Tumor vasculature function, to tag, block or destroy tumor vessel endothelium, to tag, block or destroy tumor vasculature function and inhibit angiogenesis in a tumor, and to treat or ameliorate a central nervous system disorder [P] . BRPI0514890A . 2007-11-27

机译：化合物或其药学上可接受的盐，溶剂化物或水合物，药物组合物以及抑制血管生成，抑制或降低细胞微管蛋白聚合或微管蛋白稳定性，抑制细胞中pde4活性，抑制肿瘤坏死因子-α（细胞中的tnf-alpha）活性，以治疗或改善炎症性疾病，以治疗或改善癌症，抑制癌细胞的增殖，标记，阻断或破坏肿瘤血管功能，标记，阻断或破坏肿瘤血管内皮，标记，阻断或破坏肿瘤血管系统功能并抑制肿瘤中的血管生成，并治疗或改善中枢神经系统疾病
5. methods to inhibit b cell tumor cell proliferation, to treat a patient having a tumor, to treat a patient having a deregulated taki signaling transduction molecule, to inhibit the growth of a solid tumor, to select a patient having a tumor THAT IS SUSTAINABLE to treatment with a taki inhibitor, to inhibit the proliferation of a cell leukemia and t-cell lymphomas, and to select a mammal having or methods to inhibit the proliferation of b cell tumor cell, to treat a patient having a tumor, to treat a patient having a deregulated tak1 signaling transduction molecule, to inhibit the growth of a solid tumor, to select a patient having a tumor that is susceptible to treatment with a tak1 inhibitor, to inhibit the proliferation of a cell leukemia and t-cell lymphomas, and to select a mammal having or suspected of having a tumor for treatment with a medi inhibitor tak1 [P] . BRPI0714158A2 . 2012-12-25

机译：抑制b细胞肿瘤细胞增殖，治疗患有肿瘤的患者，治疗患有taki信号转导分子失调的患者，抑制实体瘤生长，选择具有治疗可持续性的肿瘤的方法使用taki抑制剂来抑制细胞白血病和t细胞淋巴瘤的增殖，并选择具有抑制b细胞肿瘤细胞增殖的哺乳动物或方法，以治疗患有肿瘤的患者，以治疗患有t细胞淋巴瘤的患者失调的tak1信号转导分子，以抑制实体瘤的生长，选择患有对tak1抑制剂治疗敏感的肿瘤的患者，以抑制细胞白血病和t细胞淋巴瘤的增殖，并选择患有或怀疑患有肿瘤的哺乳动物可使用tak1抑制剂治疗